STA
ASND icon

Summit Trail Advisors’s Ascendis Pharma A/S ASND Stock Holding History

Summit Trail Advisors’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$343K Buy
1,287
+47
+4% +$11K ﹤0.01% 1315
2026
Q1 		$284K Buy
+1,240
New +$278K ﹤0.01% 1312

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Summit Trail Advisors's ASND Position: Q2 2026 in Review

Summit Trail Advisors increased its Ascendis Pharma A/S (ASND) stake by 3.8% in Q2 2026, buying an estimated $11K and bringing the position to 1,287 shares worth $343K. The position accounts for ﹤0.01% of the portfolio, ranked #1315.

Summit Trail Advisors first reported a position in ASND in Q1 2026 and has held it in 2 quarters since. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

  • Summit Trail Advisors held 1,287 shares of Ascendis Pharma A/S worth $343K as of Q2 2026.
  • Summit Trail Advisors bought 47 Ascendis Pharma A/S shares in Q2 2026, an estimated $11K.
  • Ascendis Pharma A/S made up ﹤0.01% of Summit Trail Advisors's portfolio in Q2 2026, its #1315 holding.
  • Summit Trail Advisors first reported a position in Ascendis Pharma A/S in Q1 2026 and has held it in 2 quarters since.
  • 312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Summit Trail Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.